References
- Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364.
- Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165(12):1425–1429.
- Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.
- Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–497.
- Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
- Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2006;13(4):236–249.
- Koyama J, Minamisawa M, Sekijima Y, et al. Left ventricular deformation and torsion assessed by speckle-tracking echocardiography in patients with mutated transthyretin-associated cardiac amyloidosis and the effect of diflunisal on myocardial function. Int J Cardiol Heart Vasc. 2015;9:1–10.
- Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2015;22(2):79–83.
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
- Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
- Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol. 2013;88(5):416–425.
- Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using (18)F florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652–1662.
- Law WP, Wang WY, Moore PT, et al. Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study. J Nucl Med. 2016;57:1733–1739.
- Butler JS, Chan A, Costelha S, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid. 2016 Jun;23(2):109–118.
- [cited 2019 Apr 30]. Availabe from: https://clinicaltrials.gov/ct2/show/NCT03702829
- [cited 2019 Apr 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03860935
- Daria A, Colombo A, Llovera G, et al. Young microglia restore amyloid plaque clearance of aged microglia. Embo J. 2017;36(5):583–603.